Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume 119, Issue 2, Pages 463-474Publisher
SPRINGER
DOI: 10.1007/s10549-009-0407-0
Keywords
Breast cancer risk; Gene-environmental interaction; Hormone metabolism; Menopausal hormone therapy; Metabolizing enzymes
Categories
Funding
- Deutsche Krebshilfe [70-2892-BR]
- Federal Ministry of Education and Research (BMBF) [01KW9975/5, 01KW9976/8, 01KW9977/0, 01KW0114]
- Robert Bosch Foundation, Stuttgart
- Department of Internal Medicine
- Evangelische Kliniken Bonn gGmbH
- Johanniter Krankenhaus, Bonn
- Deutsches Krebsforschungszentrum (DKFZ), Heidelberg
- Research Institute of Occupational Medicine of the German Social Accident Insurance (BGFA), Bochum, Germany
- BMBF Germany [01KH0401, 01KH0402, 01KH0410, 01KH0411]
Ask authors/readers for more resources
Recent findings indicate a greater risk of postmenopausal breast cancer with estrogen-progestagen therapy than estrogen monotherapy, and more so for current than past use. Few studies have examined individual genetic susceptibility to the effects of menopausal hormone therapy. We used two population-based case-control studies with 3,155 postmenopausal breast cancer patients and 5,496 controls to evaluate modification of breast cancer risk associated with duration of hormone use by genes involved in hormone metabolism and detoxification. Twenty-eight polymorphisms in eight genes of phase I (CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP3A4, CYP3A5, CYP3A7) and nine genes of phase II enzymes (COMT, GSTM1, GSTM3, GSTP1, GSTT1, SULT1A1, UGT1A1, UGT1A6, UGT2B7) were genotyped. The risk associated with duration of use of combined estrogen-progestagen therapy was significantly modified by genetic polymorphisms located in CYP1B1, GSTP1, and GSTT1. In homozygote carriers of the CYP1B1_142_G and the CYP1B1_355 _T variant alleles, adjusted odds ratios (OR) per year of use were 1.06 (95% confidence interval (CI) = 1.02-1.09) and 1.06 (95% CI = 1.03-1.09), respectively, compared with 1.02 (95% CI = 1.01-1.03) in non-carriers of either polymorphism (p (interaction) = 0.01). Carriers of the functional GSTT1 allele and the GSTP1_341_T allele were at significantly higher risks associated with hormone use compared with non-carriers (p (interaction) = 0.0001 and 0.02). CYP1A1_2452_C > A significantly reduced the risk associated with duration of use of estrogen monotherapy (p (interaction) = 0.01). The finding regarding GSTT1 was still statistically significant after corrections for multiple comparisons. Postmenopausal breast cancer risk associated with hormone therapy may be modified by genetically determined variations in phase I and II enzymes involved in steroid hormone metabolism.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available